title: Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
authors.affiliation: Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil. lnader@terra.com.br
authors.forename: Lysandro Alsina
authors.initials: LA
authors.lastname: Nader
authors.forename: Angelo Alves
authors.initials: AA
authors.lastname: de Mattos
authors.forename: Pedro Dornelles
authors.initials: PD
authors.lastname: Picon
authors.forename: Sérgio Luis
authors.initials: SL
authors.lastname: Bassanesi
authors.forename: Angelo Zambam
authors.initials: AZ
authors.lastname: De Mattos
authors.forename: Margarita
authors.initials: M
authors.lastname: Pineiro Rodriguez
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000453:epidemiology*; D015331:Cohort Studies; D015897:Comorbidity; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D006526:Hepatitis C / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D016896:Treatment Outcome; D014376:Tuberculosis / Q000097:blood / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D000998:Antiviral Agents; D015483:HIV Antibodies; D018937:Hepatitis C Antibodies; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin